Aripiprazole 및 Aripiprazole Monthly(Abilify Maintena) 대체 병합 투여로 증상 악화를 보인 만성 조현병 환자
Worsening of Psychotic Symptoms in Patients with Chronic Schizophrenia after Switching to or Combining Aripiprazole and Aripiprazole Monthly (Abilify Maintena)
0
조회
0
다운로드
0
인용
0
참고문헌
초록
Objectives Aripiprazole is an antipsychotic that functions as a partial agonist in hypodopaminergic states and a dopamine antagonist in hyperdopaminergic states. Methods This paper reports a series of five clinical cases of worsening psychotic symptoms in schizophrenic patients related to the initiation of aripiprazole, oral and injection, as combination therapy. Results In all five cases, the switching of aripiprazole improved the psychotic symptoms. Conclusion Even with the suggestive relationship between aripiprazole therapy and the worsening of psychotic symptoms, further research is needed.
Abstract
Objectives Aripiprazole is an antipsychotic that functions as a partial agonist in hypodopaminergic states and a dopamine antagonist in hyperdopaminergic states. Methods This paper reports a series of five clinical cases of worsening psychotic symptoms in schizophrenic patients related to the initiation of aripiprazole, oral and injection, as combination therapy. Results In all five cases, the switching of aripiprazole improved the psychotic symptoms. Conclusion Even with the suggestive relationship between aripiprazole therapy and the worsening of psychotic symptoms, further research is needed.
참고문헌 (9)
- DeLeon A, "Aripiprazole: a comprehensive review of its pharmacology, clinical efficacy, and tolerability", Clin Ther, 26, pp.649~666 (2004)
- Lawler CP, "Interactions of the novel antipsychotic aripiprazole(OPC-14597)with dopamine and serotonin receptor subtypes", Neuropsychopharmacology, 20, pp.612~627 (1999)
- Marder SR, "Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials", Schizophr Res, 61, pp.123~136 (2003)
- Potkin SG, "Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder", Arch Gen Psychiatry, 60, pp.681~690 (2003)
- "FDA Drug Safety Podcast: FDA warns about new impulse-control problems associated with mental health drug aripiprazole (Abilify, Abilify Maintena, Aristada)" (2016)[URL]
- Roxanas MG, "Pathological gambling and compulsive eating associated with aripiprazole", Aust N Z J Psychiatry, 44, pp.291~ (2010)
- Ahlskog JE, "Pathological behaviors provoked by dopamine agonist therapy of Parkinson’s disease", Physiol Behav, 104, pp.168~172 (2011)
- Heres S, "Treatment of early episode in patients with schizophrenia: the role of long acting antipsychotics", Eur Psychiatry, 29(Suppl 2), pp.1409~1413 (2014)
- Takaesu Y, "Factors associated with discontinuation of aripiprazole treatment after switching from other antipsychotics in patients with chronic schizophrenia:a prospective observational study", Psychiatry Res, 236, pp.71~74 (2016)